Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial

Corinne Faire-Finn, MD, PhD, David Vicente, MD, Takayasu Kurata, MD, David Planchard, MD, PhD, Luis Paz-Ares, MD, PhD, Johan F. Vansteenkiste, MD, PhD, David R. Spigel, MD, Marina C. Garassino, MD, Martin Reck, MD, Suresh Senan, PhD, Jarushka Naidoo, MBBCH, MHS, Andreas Rümmer, MD, Yi-Long Wu, MD, Jhanelle E. Gray, MD, Mustafa Özgüro, Terufumi Kato, MD, Maike de Wit, MD, Michael Newton, PharmD, Lu Wang, PhD, Piruntha Thiyagarajah, MD, Scott J. Antonia, MD, PhD*

*Brief Report

Disclosure: Dr. Faire-Finn reports receiving research funding from AstraZeneca, Elekta, and NIHR Manchester Biomedical Research Centre; and travel support from AstraZeneca, and Elekta. Dr. Vicente reports receiving research funding from AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, and Roche; and honoraria from AstraZeneca, Pfizer, Bristol-Myers Squibb, Merck Sharp & Dohme, Novartis, Daiichi Sankyo, and Chugai; and honoraria from AstraZeneca, Eli Lilly, Merck Sharp & Dohme, Ono, Boehringer Ingelheim, Bristol-Myers Squibb, and Chugai. Dr. Kurata reports receiving research funding from AstraZeneca, Merck Sharp & Dohme, Boehringer Ingelheim, Novartis, Eli Lilly, and Chugai; and honoraria from AstraZeneca, Eli Lilly, Merck Sharp & Dohme, and Ono. Dr. Planchard reports receiving research funding, consulting, advisory, and/or speakers’ bureau fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, Pfizer, prIME Oncology, Peers CME, Roche, and Samsung. Dr. Paz-Ares reports receiving consulting, advisory, and/or speakers’ bureau fees from Merck Sharp & Dohme, Bristol-Myers Squibb, Roche, AstraZeneca, Eli Lilly, Merck, Novartis, Amgen, Incyte, Takeda, PharmoMar, Ipsen, Blueprint, and Bayer; and has board membership for Altum Sequencing and Genomica. Dr. Vansteenkiste reports receiving research funding from Merck Sharp & Dohme; and consulting, advisory, and/or speakers’ bureau fees from AstraZeneca, Boehringer Ingelheim, Merck Sharp & Dohme, Novartis, Roche, Pfizer, and Bristol-Myers Squibb. Dr. Spigel reports receiving research funding from AstraZeneca, Genentech/Roche, Novartis, and Celgene; Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, AbbVie, Foundation Medicine, GlaxoSmithKline, Eli Lilly, Merck, Nektar, and Takeda. Dr. Faire-Finn is with the University of Texas Southwestern Medical Center-Simmons Cancer Center, G1 Therapeutics, Neon Therapeutics, Celldex, Clovis Oncology, Daiichi Sankyo, EMD Serono, Astellas Pharma, GRAIL, Transgene, Aeglea Therapeutics, Tesaro, Ipsen, Janssen, BIND Therapeutics, Eisai, and ImClone Systems; and consulting; and consulting, advisory, and/or speakers’ bureau fees from AstraZeneca, Genentech/Roche, Novartis, Celgene, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, AbbVie, Foundation Medicine, GlaxoSmithKline, Eli Lilly, Merck, Moderna, Nektar, Takeda, Amgen, TRM Oncology, Precision Oncology, Evelo Therapeutics, Illumina, Pharmamar, EMD Serono, Apital Health, Dracen Pharmacologica, Iskusa Therapeutics, Molecular Templates, Seattle Genetics, Triptych Health Partners, and Intellisphere. Dr. Garassino reports receiving research funding from Bristol-Myers Squibb, Merck Sharp & Dohme, Roche/Genentech, AstraZeneca, Pfizer, GlaxoSmithKline, Novartis Merck, Incyte, Takeda, Spectrum Pharmaceuticals, and Blueprint Medicine; consulting; and consulting, advisory, and/or speakers’ bureau fees from Bristol-Myers Squibb, Merck Sharp & Dohme, AstraZeneca, Novartis, Takeda, Roche, Tiziana Life Sciences, Sanofi, Celgene, Daiichi Sankyo, Inhibica, Incyte, Pfizer, Spectrum Pharmaceuticals; Janssen; Medimmune; GlaxoSmithKline; Eli Lilly and Otsuka; accommodations, expenses from Pfizer, Roche, and AstraZeneca; and honoraria from Merck Sharp & Dohme, AstraZeneca, GlaxoSmithKline, Takeda, Roche, Bristol-Myers Squibb. Dr. Reck reports receiving consulting, advisory, and/or speakers’ bureau fees from AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Eli Lilly, Merck and Company, Novartis, Pfizer, Roche, and Sanofi. Dr. Gray reports receiving research funding from Genentech, Merck, Bristol-Myers Squibb, Regeneron, Eli Lilly, Merck KGA, Novartis, and Boehringer Ingelheim; and consulting, advisory, and/or speakers’ bureau fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Merck Sharp & Dohme, Pfizer, and Sanofi. Dr. Lee reports receiving consulting, advisory, and/or speakers’ bureau fees from Bristol-Myers Squibb, Merck Sharp & Dohme, AstraZeneca, and Pfizer. Dr. Cho reports receiving research funding from Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST, Champions Oncology, Janssen, Yuhan, Ono, Daiya Pharma, and Merck Sharp & Dohme; consulting, advisory, and/or speakers’ bureau fees from Novartis, AstraZeneca, Boehringer Ingelheim, Roche, BMS, Ono, Yuhan, Pfizer, Eli Lilly, Janssen, Takeda, Merck Sharp & Dohme; and stock ownership in TeraConVic, Inc. Dr. Kato reports receiving research funding from AstraZeneca, AbbVie, Amgen, Bristol-Myers Squibb, Chugui, Eli Lilly, Merck, Merck Sharp & Dohme, Novartis, Ono, Pfizer, Taiho, Asielas, Kyorin, Kyowa-Kirin and Regeneron; and consulting, advisory, and/or speakers’ bureau fees from AbbVie, Amgen, Bristol-Myers Squibb, Chugui, Eli Lilly, Merck, Merck Sharp & Dohme, Novartis, Ono, Pfizer, Taiho, Boehringer Ingelheim, Daiichi Sankyo, F. Hoffmann-La Roche, Nippon Kayaku, Nitta Denko, Shionogi, Sumitomo Dainippon, and Takeda. Dr. de Wit reports receiving consulting, advisory, and/or speakers’ bureau fees from AstraZeneca. Drs. Newton, Wang, and Thiyagarajah report receiving employment and stock ownership with AstraZeneca. Dr. Antonio reports receiving consulting, advisory, and/or speakers’ bureau fees from Bristol-Myers Squibb, Novartis, Merck, AstraZeneca, Boehringer Ingelheim, Cellular Biomedicine Group, and Memgen. Dr. Özgüroğlu declares no conflict of interest.

Address for correspondence: Corinne Faire-Finn, MD, PhD, The Christie National Health Service Foundation Trust, Wilmots Rd, Manchester M20 4BX, United Kingdom. E-mail: corinne.finn@nhs.net

© 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

ISSN: 1556-0864

As of March 20, 2020 (median follow-up analyzed using a stratified log-rank test in the intent-to-treat population. Medians and 4-year OS and PFS rates were estimated by the Kaplan–Meier method.

Results: Overall, 709 of 713 randomized patients received durvalumab (n/N=473/476) or placebo (n/N=236/237). As of March 20, 2020 (median follow-up = 34.2 months; range: 0.2–64.9), updated OS (HR = 0.71; 95% CI: 0.57–0.88) and PFS (HR = 0.55; 95% CI: 0.44–0.67) remained consistent with the primary analyses. The median OS for durvalumab was reached (47.5 mo; placebo, 29.1 months). Estimated 4-year OS rates were 49.6% versus 36.3% for durvalumab versus placebo, and 4-year PFS rates were 35.3% versus 19.5% respectively.

Conclusion: These updated exploratory analyses demonstrate durable PFS and sustained OS benefit with durvalumab after chemoradiotherapy. An estimated 49.6% of patients randomized to durvalumab remain alive at 4 years (placebo, 36.3%), and 35.3% remain alive and progression-free (placebo, 19.5%).

© 2021 International Association for the Study of Lung Cancer. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: Durvalumab; Locally advanced NSCLC; PACIFIC; Overall survival; Progression-free survival

Introduction

Until recently, platinum-based, concurrent chemoradiotherapy (CRT) followed by observation was the standard of care for patients with unresectable, stage III NSCLC and good performance status. However, patient
prognosis was poor, with a 5-year survival rate of approximately 15% to 32%. Moreover, there was no evidence that continuing chemotherapy, utilizing other systemic anticancer agents after CRT, or escalating the radiation dose could improve survival.

Durvalumab is a selective, high-affinity, human immunoglobulin G1 monoclonal antibody that blocks the interaction of programmed death-ligand 1 (PD-L1) with programmed cell death protein 1 and CD80, allowing T-cells to recognize and kill tumor cells (TCs). In the placebo-controlled, phase-3 PACIFIC trial of patients with unresectable, stage III NSCLC whose disease did not progress after concurrent CRT, consolidative durvalumab (≤12 months) significantly prolonged overall survival (OS) (stratified hazard ratio [HR] = 0.68; 95% confidence interval [CI]: 0.53–0.87; \( p = 0.00251 \); median, not reached versus 28.7 months; data cutoff March 22, 2018) and progression-free survival (PFS) (stratified HR = 0.52; 95% CI: 0.42–0.65; \( p < 0.0001 \); median, 16.8 versus 5.6 months; data cutoff February 13, 2017). Durvalumab exhibited a manageable safety profile and did not detrimentally impact patient-reported quality of life.

The OS benefit with durvalumab was sustained at an updated analysis that took place approximately 3 years after the last patient was randomized to PACIFIC (stratified HR = 0.69; 95% CI: 0.55–0.86; data cutoff January 31, 2019). Here, we report updated OS, and PFS, from a preplanned, exploratory analysis of PACIFIC, approximately 4 years after the last patient was randomized, including the first estimate of median OS for the durvalumab arm.

**End Points and Assessments**

In this exploratory analysis, we report the data up to March 20, 2020, including updates of the following: (1) OS and PFS (blinded independent central review; Response Evaluation Criteria in Solid Tumors version 1.1) for the intent-to-treat (ITT) population; (2) OS and PFS rates at 12, 24, 36, and 48 months; (3) the types of postdiscontinuation disease-related anticancer therapies administered; and (4) time to first and time to second subsequent therapy or death. Furthermore, we updated the analyses of OS and PFS in patient subgroups defined by prespecified and post hoc baseline factors. This included PD-L1 status, which was determined on the basis of testing of archived, pre-CRT tumor tissue and analyzed at prespecified (25%) and exploratory post hoc (1%) PD-L1 TC expression thresholds (using the Ventana SP263 immunohistochemistry assay [Ventana Medical Systems, Tuscon, AZ]). Safety data were not collected at this data cutoff.

**Statistical Analysis**

For time-to-event end points, treatment effects for durvalumab versus placebo were estimated from HRs calculated using a stratified log-rank test in the ITT population (with the same stratification factors used for randomization). Unstratified Cox proportional hazards models were used to calculate treatment effects in patient subgroups; no adjustment for multiple comparisons was performed. Medians and landmark rates (e.g., 48-month OS and PFS rates) were estimated using the Kaplan–Meier method.

**Results**

**Patients**

In total, 709 of 713 randomized patients received treatment in the durvalumab (n/N = 473/476) and placebo arms (n/N = 236/237); the last patient completed protocol-defined 12-month study treatment in May 2017. The baseline characteristics were well balanced between the durvalumab and placebo arms, as reported previously. As of March 20, 2020, 51.9% and 62.9% of patients randomized to durvalumab and placebo, respectively, had died (Supplementary Fig. 1). The median duration of follow-up was 34.2 months (range: 0.2–64.9).
Overall Survival

In total, 97 additional deaths were reported since the primary analysis of OS (March 22, 2018), and 52 new deaths were reported since the last update of the OS analysis (January 31, 2019). Updated OS was consistent with the primary analysis; there was a 29% reduction in the risk of death with durvalumab (stratified HR = 0.71; 95% CI: 0.57–0.88) (Fig. 1A). The Kaplan–Meier estimate of median OS was reached for durvalumab (47.5 months; placebo, 29.1 months). The 48-month OS rate was estimated as 49.6% for durvalumab versus 36.3% for placebo.

Figure 1. Updated (A) OS and (B) PFS in the ITT population. PFS was assessed by BICR. Vertical tick marks indicate censored observations. OS is defined as the time from randomization until death from any cause. PFS is defined as the time from randomization to the date of the first documented event of tumor progression or death in the absence of disease progression. BICR, blinded independent central review; CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; OS, overall survival; PFS, progression-free survival.
In total, 69 additional PFS events were reported since the primary analysis of PFS (February 13, 2017), and 24 new PFS events were reported since the primary analysis of OS (March 22, 2018). Updated PFS was consistent with the primary analysis; there was a 45% reduction in the risk of disease progression or death with durvalumab (stratified HR = 0.55; 95% CI: 0.40–0.87).

### Figure 2.
Updated OS by prespecified and post hoc exploratory subgroups. *HRs and 95% CIs were not calculated if the subgroup had less than 20 events. CI, confidence interval; EGFR, epidermal growth factor receptor; HR, hazard ratio; OS, overall survival; PD-L1, programmed death-ligand 1; WHO, World Health Organization.

### Progression-Free Survival
In total, 69 additional PFS events were reported since the primary analysis of PFS (February 13, 2017), and 24 new PFS events were reported since the primary analysis of OS (March 22, 2018). Updated PFS was consistent with the primary analysis; there was a 45% reduction in the risk of disease progression or death with durvalumab (stratified HR = 0.55; 95% CI: 0.40–0.87).
The Kaplan–Meier estimate of median PFS was 17.2 months and 5.6 months for durvalumab and placebo, respectively. The 48-month PFS rate was estimated as 35.3% for durvalumab versus 19.5% for placebo. Updated analyses of PFS by subgroup were consistent with the previous reports (Fig. 3)[6,13]; PFS benefit favored durvalumab across all PD-L1 subgroups (Supplementary Fig. 3).
Postdiscontinuation Anticancer Therapy

After discontinuing the study treatment, 47.3% and 58.2% of patients received subsequent disease-related anticancer therapy in the durvalumab and placebo arms, respectively (Supplementary Table 1); 11.6% and 28.3% received subsequent immunootherapy, respectively. Consistent with the results reported at the time of the primary analysis of OS, the time to first subsequent therapy or death (stratified HR = 0.62; 95% CI: 0.51–0.76) and the time to second subsequent therapy or death (stratified HR = 0.62; 95% CI: 0.51–0.77) were longer with durvalumab versus placebo (Supplementary Fig. 4).

Discussion

These updated results demonstrate that durvalumab provides sustained survival benefit over the longer term. At 4 years, an estimated 49.6% of patients randomized to durvalumab were alive (placebo, 36.3%), and 35.3% were alive and free of disease progression (placebo, 19.5%). Notably, the median OS for the durvalumab arm was reached at this update (47.5 months; placebo, 29.1 months). OS and PFS favored durvalumab versus placebo across almost all prespecified patient subgroups, including subgroups defined by age, sex, race, disease stage, tumor histologic type, smoking status, and CRT-related variables, supporting the use of the PACIFIC regimen as the standard of care in a broad population. Nevertheless, the subgroup analyses are limited by small sample sizes and none were statistically powered to assess efficacy, nor were they necessarily balanced with respect to other baseline factors.

The PACIFIC trial was designed as an all-comers study and not to evaluate clinical outcomes according to any tumor biomarker status. Consistent OS and PFS benefit with durvalumab was observed across all prespecified subgroups with the exception of the EGFR-positive subgroup, for which survival benefit was uncertain. However, the small size of this subgroup (N = 43) and the exploratory nature of the analysis preclude definitive conclusions.

Consistent with previous analyses from the PACIFIC study,10 OS and PFS benefit favored durvalumab versus placebo across all PD-L1 subgroups with the exception of OS in patients with PD-L1 expression on less than 1% of TCs (HR = 1.05; 95% CI: 0.69–1.62), despite PFS favoring durvalumab in this post hoc subgroup. However, as reported previously, the PD-L1 subgroup analyses are limited by the relatively small number of patients with PD-L1 expression on less than 1% of TCs, the use of pre-CRT tumor samples to assess PD-L1 expression, and the incomplete provision of tumor tissue; PD-L1–assessable samples were available for only 63% of all randomized patients.15,16 Moreover, with respect to OS, the placebo arm overperformed in the PD-L1 TC less than 1% subgroup compared with the ITT population; this may be accounted for by imbalances in potentially prognostic baseline factors, as described previously.13 Therefore, robust conclusions regarding the impact of PD-L1 expression on efficacy cannot be drawn.

Fewer patients in the durvalumab arm received subsequent anticancer treatment compared with the placebo arm. This was likely driven by improved PFS and fewer progression events observed with durvalumab. Notably, fewer patients received subsequent immuno-therapy in the durvalumab arm (11.6%) compared with the placebo arm (28.3%), but this did not negate the OS benefit with the PACIFIC regimen. Otherwise, the proportions of patients who received subsequent treatment with each type of anticancer therapy were similar between the durvalumab and placebo arms. Likely owing to the time of initiation of the trial and the standards of care in systemic therapy at that time, chemotherapy was the most common subsequent therapy across both arms.

In conclusion, these updated, exploratory analyses from PACIFIC demonstrate durable PFS and sustained OS benefit with the standard-of-care PACIFIC regimen (durvalumab after CRT). An estimated 49.6% of patients randomized to durvalumab remain alive at 4 years (placebo, 36.3%), and an estimated 35.3% remain alive and progression-free (placebo, 19.5%).

Acknowledgments

This study (NCT02125461) was sponsored by AstraZeneca. Medical writing support, which was in accordance with Good Publication Practice (GPP3) guidelines, was provided by Aaron Korpal, PhD, of Cirrus Communications (Manchester, United Kingdom), an Ashfield company, and was funded by AstraZeneca. Dr. Faivre-Finn is supported by a grant from the National Institute for Health Research (NIHR) Manchester Biomedical Research Centre. Dr. Rimner is supported, in part, by a grant from the National Institutes of Health/National Cancer Institute Cancer Center (support grant: P30 CA008748).

Supplementary Data

Note: To access the supplementary material accompanying this article, visit the online version of the Journal of Thoracic Oncology at www.jto.org and at https://doi.org/10.1016/j.jtho.2020.12.015.

References


